First Tracks Biotherapeutics (TRAX) — Cash Flow-to-Debt Ratio
Latest as of June 2026:
-2.23x
First Tracks Biotherapeutics (TRAX) has a Cash Flow-to-Debt Ratio of -2.23x as of June 2026, meaning its operating cash flow of $-31.92 Million could theoretically repay -2% of its total liabilities ($14.34 Million) in one year. See how financially flexible is First Tracks Biotherapeutics to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
-2.23x
Operating CF / Total Liabilities
Operating Cash Flow
$-31.92 Million
USD
Total Liabilities
$14.34 Million
USD
Data as of
Jun 2026
Most recent filing
First Tracks Biotherapeutics Cash Flow-to-Debt Ratio (2023–2025)
Historical debt coverage capacity for First Tracks Biotherapeutics across 3 annual periods. For the full cash flow conversion analysis, see First Tracks Biotherapeutics operating cash flow efficiency.
Annual Cash Flow-to-Debt Ratio for First Tracks Biotherapeutics (2023–2025)
Year-by-year debt coverage analysis for First Tracks Biotherapeutics.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.32x | $-142.93 Million | $43.05 Million | ▼ -32.7% |
| 2024 | -2.50x | $-125.81 Million | $50.30 Million | ▲ +7.9% |
| 2023 | -2.71x | $-93.00 Million | $34.26 Million | — |
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.